Aktie A2G84A HARVARD APPARATUS REGENERATIVE TECHNOLOGY INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Harvard Apparatus Regenerative Technology Inc.

Aktien

A2G84A

US09074M2026

HRGN

Markt geschlossen - OTC Markets
Andere Börsenplätze
 19:39:40 25.04.2024 		% 5 Tage % 1. Jan.
2,39 USD +3,02 % Intraday Chart für Harvard Apparatus Regenerative Technology Inc. +3,02 % -52,10 %
28.03. Harvard Apparatus Regenerative Technology Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI
2023 Harvard Apparatus Regenerative Technology Inc. meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 30. September 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Harvard Apparatus Regenerative Technology Inc. announced that it expects to receive $1.482101 million in funding
Harvard Apparatus Regenerative Technology Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Harvard Apparatus Regenerative Technology : March 19, 2024 - Investor Presentation
Harvard Apparatus Regenerative Technology : Q4 - 2023 HBIO Quarterly Earnings Presentation
Harvard Apparatus Regenerative Technology Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Harvard Apparatus Regenerative Technology : Northland Capital Markets Institutional Investor Conference 2023
Harvard Apparatus Regenerative Technology Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Harvard Apparatus Regenerative Technology : Q2 - 2023 HBIO Quarterly Earnings Presentation
Biostage Activated Mayo Clinic as the First Site for Clinical Trial in Severe Esophageal Disease
Biostage, Inc. Activated Mayo Clinic as the First Site for Clinical Trial in Severe Esophageal Disease
Purcell & Lefkowitz LLP Is Investigating Biostage, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
Biostage to Host Investor Call
Biostage Initiated Study Start-up Activities for Clinical Trial in Severe Esophageal Disease
Biostage, Inc. Initiates Study Start-Up Activities for Clinical Trial in Severe Esophageal Disease
Biostage Initiates Study Start-Up Activities for Clinical Trial in Severe Esophageal Disease
Biostage, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Biostage, Inc. announced that it has received $6.005802 million in funding
BIOSTAGE, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
Biostage Appoints Ron Packard to Board of Directors
Biostage, Inc. Appoints Ron Packard to Board of Directors
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2G84A Aktie
  4. Nachrichten Harvard Apparatus Regenerative Technology Inc.
  5. Andere Sprachen